Shares of Regeneron Pharmaceuticals Inc. REGN shed 6.87% to $568.91 Tuesday, on what proved to be an all-around great trading ...

The FDA does not plan a reorganization of the agency but will consolidate offices that handle travel and IT ...

Regeneron Pharmaceuticals' first-quarter net income rose but revenue fell due to inventory issues and generic competition for its best-selling biopharmaceuticals, and the company trimmed its ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

The Tarrytown, New York-based company said it had profit of $7.27 per share. Earnings, adjusted for one-time gains and costs, came to $8.22 per share. The results fell short of Wall Street ...

Regeneron (REGN) came out with quarterly earnings of $8.22 per share, missing the Zacks Consensus Estimate of $8.43 per share. This compares to earnings of $9.55 per share a year ago. These ...

Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...